The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis

被引：0

作者：

Pan, L. ^{[1
]}

Xu, Z. ^{[2
]}

Yu, W. ^{[3
]}

Shen, X. ^{[4
]}

Zhang, Z. ^{[5
]}

Jiao, Z. ^{[6
]}

Zhao, X. ^{[7
]}

Hou, M. ^{[8
]}

Du, X. ^{[9
]}

Ma, H. ^{[10
]}

Duan, M. ^{[11
]}

Peng, H. ^{[12
]}

Yang, M. ^{[13
]}

Wang, W. ^{[14
]}

Gong, T. ^{[15
]}

Ding, D. ^{[16
]}

Wang, D. ^{[16
]}

Xiao, Z. ^{[2
]}

机构：

[1] Sichuan Univ, Dept Hematol, West China Hosp, Chengdu, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[3] Binzhou Med Coll, Affiliated Hosp, Dept Hematol, Binzhou, Peoples R China

[4] Changzhi Med Coll, Heping Hosp, Dept Hematol, Changzhi, Peoples R China

[5] Chengde Med Univ, Affiliated Hosp, Dept Hematol, Chengde, Peoples R China

[6] Xingtai Peoples Hosp, Dept Hematol, Xingtai, Peoples R China

[7] Tianjin Peoples Hosp, Dept Hematol, Tianjin, Peoples R China

[8] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Peoples R China

[9] Guangdong Prov Peoples Hosp, Dept Hematol, Guangzhou, Peoples R China

[10] Cangzhou Peoples Hosp, Dept Hematol, Cangzhou, Peoples R China

[11] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[12] Cent South Univ, Xiangya Hosp 2, Dept Hematol, Changsha, Peoples R China

[13] Anhui Med Univ, Affiliated Hosp 1, Dept Hematol, Hefei, Peoples R China

[14] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao, Peoples R China

[15] Harbin First Hosp, Dept Hematol, Hematol Res Ctr, Harbin, Peoples R China

[16] Chia Tai Tianqing Pharmaceut Grp Co Ltd, Clin Res Ctr, Nanjing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.850

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

799MO

引用

页码：S596 / S596

页数：1